Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795073 | 0.79 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1ALDH1A1LMNA | |
| SCHEMBL5794842 | 0.77 | LIMK1 (0.50) | HSP90AA1ALDH1A1LMNA | |
| SCHEMBL2378228 | 0.76 | P2RX1 (0.53) | ALDH1A1LMNA | |
| SCHEMBL10666350 | 0.75 | GPR55 (0.54) | ALDH1A1LMNA | |
| SCHEMBL5797317 | 0.75 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1ALDH1A1LMNA | |
| SCHEMBL5793740 | 0.73 | ALDH1A1 (0.64) | HSP90AA1HSP90AB1ALDH1A1LMNA | |
| SCHEMBL10667310 | 0.71 | CA5A (0.57) | — | |
| SCHEMBL6072189 | 0.71 | CYP19A1 (0.48) | TACR1ALDH1A1 | |
| SCHEMBL9989826 | 0.70 | CYP19A1 (0.66) | HSP90AA1HSP90AB1 | |
| SCHEMBL24208572 | 0.69 | TGM2 (0.66) | HSP90AA1HSP90AB1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | TACR1 1/4885HSP90AA1 2007/4885HSP90AB1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.